Pharma Disease Insight: Gastric Cancer (PowerPoint PPTX Slide Deck)

In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal junction (GEJ) adenocarcinoma. We expect that major-market sales will rapidly increase over the forecast period, totaling almost $9.5 billion in 2025. This growth will be predominantly fuelled by the approval of seven agents in the indication, and also by Cyramza (Eli Lilly's ramucirumab).

The entry of three PD-1/PD-L1 inhibitors into the gastric and GEJ adenocarcinoma market (Merck & Co.'s Keytruda [pembrolizumab], Bristol Myers-Squibb/Ono Pharmaceutical's Opdivo [nivolumab], and Merck KGaA/Pfizer's avelumab) will significantly drive growth during the forecast period. We also forecast the approval of Yervoy (Bristol Myers-Squibb/Ono Pharmaceutical's ipilimumumab) to be used in conjunction with Opdivo.

INTRODUCTION
1. Key Findings
2. Market Share of Colorectal Cancer Drug Classes in 2015 and 2025
3. Disease Market SWOT Analysis
ETIOLOGY AND PATHOPHYSIOLOGY
1. Key Findings
2. Expert Insight
3. Disease Overview
4. Disease Pathophysiology
5. Etiology
6. Pathophysiology
KEY PATHWAYS AND DRUG TARGETS
MARKET OUTLOOK
1. Key Findings
2. Expert Insight
3. Market Overview
4. What Factors Are Driving the Market
5. What Factors Are Constraining the Market